Product Description
Diacerein is a symptomatic slow-acting drug in osteoarthritis (SYSADOA) with anti-inflammatory, anti-catabolic and pro-anabolic properties on cartilage and synovial membrane.
Mechanisms of Action: IL1B Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Argentina | Austria | Bangladesh | Brazil | Chile | Colombia | Czech | Ecuador | Egypt | France | Greece | Hong Kong | India | Indonesia | Israel | Italy | Jordan | Korea | Malaysia | Mexico | Morocco | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Slovakia | Spain | Thailand | Turkey | Ukraine | Uruguay | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Castle Creek
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Austria, Belgium, France, Greece, Ireland, Italy, Poland, Thailand
Active Clinical Trial Count: 2
Highest Development Phases
Phase 3: Epidermolysis Bullosa Simplex|Osteoarthritis, Knee
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| DAR-THA-19-01 | P3 |
Recruiting |
Osteoarthritis, Knee |
2026-12-31 |
|
| AC-203-EBS-007 | P3 |
Unknown Status |
Epidermolysis Bullosa Simplex |
2026-03-31 |